EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”.
EuropaBio, the European Association for Bioindustries, has announced its “top five biotech SMEs in Europe”. The companies will compete to win the 5th annual Most Innovative EU Biotech SME Award, to be awarded during European Biotech Week (October 8) in Brussels, Belgium.
Shortlisted are:
Autifony (London, UK): A healthcare biotech based at Imperial College London, focused on the development of high value novel medicines to treat hearing disorders and serious disorders of the central nervous system, such as schizophrenia.
Bio-on (Bologna, Italy): Bio-on works in industrial biotechnology applied to widely used materials, creating natural products and solutions based on renewable resources or on agricultural processing waste material.
Biosyntia (Horshølm, Denmark): An industrial biotech SME, providing unique fermentation solutions to chemical manufacturing companies.
Erytech Pharma (Lyon, France): A biopharmaceutical company developing an innovative concept to starve cancer cells in specific essential nutrients, and quickly induce their death without impairing any healthy cells.
to-BBB (Leiden, The Netherlanda): A biotech developing novel treatments for patients with devastating brain diseases. Its lead clinical programs target multiple types of brain cancers, including brain metastases from breast cancer, as well as neuro-inflammatory diseases.
This year’s award ceremony reportedly has a focus on financing, with the European Investment Bank presenting its Growth Financing Facility for funding innovative companies in the EU, and the European Commission illustrating its SME Instrument under Horizon 2020.
Click here for further information.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.